Investment
Features
FeesSafety
Academy
More
Pluang+

Compare DexCom, Inc. (DXCM) vs Oracle Corporation (ORCL) Price & Performance

DexCom, Inc.Trade
Oracle CorporationTrade

Price performance (Past 24H)

Key statistics

DexCom, Inc. vs Oracle Corporation — how do they compare? DexCom, Inc. trades at $90.05 (market cap $33.79B), while Oracle Corporation trades at $152.3 (market cap $419.05B). The key difference: Oracle Corporation is far larger — about 12.4× DexCom, Inc.'s market cap, and Oracle Corporation pays a 1.37% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.

DXCMORCL
Market Cap
$33.79B$419.05B
Sector
HealthTechnology
52-Week High
$89.53$328.33
52-Week Low
$54.84$114.99
Enterprise Value
$33.24B$548.30B
Dividend Yield
1.37%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

DexCom, Inc.

DXCM trades at $90.23, up 2.94% today and near its 52-week high, with a bullish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating EPS estimates with $0.70 versus $0.61 expected, and raised full-year guidance. Revenue growth remains robust at 13% year-over-year, supported by G7 system adoption and international expansion. Profit margins improved, with net income margin reaching 20.12% in 2025. Analyst sentiment is overwhelmingly positive, with 80% buy ratings.

The outlook for DXCM is favorable due to sustained demand for continuous glucose monitors and strategic initiatives like 'Road to 100'. Key risks include competitive pressures, regulatory scrutiny, and valuation multiples above industry averages. The stock's current price is slightly above the consensus target of $88.65, suggesting near-term consolidation may occur before further upside.

Oracle Corporation

Oracle Corporation (ORCL) trades at $151.04, up 2.79% with strong technical momentum. The stock shows robust fundamentals with 21.67% net profit margin and consistent earnings beats in recent quarters. Oracle's AI infrastructure positioning and partnership with OpenAI have driven investor optimism, though RSI levels suggest potential overbought conditions. The company maintains solid cash flow generation with $20.82B from operations in 2025.

Oracle presents a compelling growth story with AI-driven revenue acceleration and strong analyst support (65% buy ratings). Key risks include high valuation multiples and significant debt load. The consensus price target of $252.44 implies substantial upside, but investors should monitor execution on AI investments and competitive pressures in cloud infrastructure.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About DexCom, Inc.

Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.

Read more on DXCM

About Oracle Corporation

Oracle provides database technology and enterprise resource planning, or ERP, software to enterprises around the world. Founded in 1977, Oracle pioneered the first commercial SQL-based relational database management system. Today, Oracle has 430,000 customers in 175 countries, supported by its base of 136,000 employees.

Read more on ORCL